Tetanus Immune Globulin (TIG)

Treatment for Tetanus

Typical Dosage: 3000-6000 IU IM or IV, depending on severity and formulation

Effectiveness
90%
Safety Score
75%
Clinical Trials
8
Participants
5K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
MethπŸ’€
Cigarettes🚬
Chemo☒️
Alcohol🍺
MorphineπŸ’Š
AntibioticsπŸ’‰
TylenolπŸ’Š
ExerciseπŸƒ
WaterπŸ’§
75
DangerousModerateSafe
Treatment Details
Dosage Range
3000-6000 IU IM or IV, depending on severity and formulation
Time to Effect
Immediate (neutralizes unbound toxin)
Treatment Duration
Single dose (sometimes repeated)
Evidence Quality
HIGH
Number Needed to Harm (NNH)
200(Treat 200 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$1,500
Monitoring:$50
Side Effect Mgmt:$20
Total Annual:$1,570
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
QALYs Gained
15
Outcome-Based Costs
Cost per Responder
$1,847
Cost per Remission
$2,243
Tetanus Immune Globulin (TIG) Outcomes

for Tetanus

Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+85%
Remission Rate
+70%
Common Side Effects
Local pain/tenderness at injection site
+15%
Fever
+5%
Allergic reactions (rash, itching)
+1%

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
3 active trials recruiting for Tetanus Immune Globulin (TIG) in Tetanus

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection

NCT07149454ENROLLING BY INVITATIONPHASE1
View Study
68 participants
INTERVENTIONAL
Lanzhou, China
Started: Aug 18, 2025

A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection

NCT06635798RECRUITINGPHASE3
View Study
582 participants
INTERVENTIONAL
Hefei, China +19 more
Started: Sep 3, 2024

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants

NCT06939777NOT YET RECRUITINGPHASE1, PHASE2
View Study
255 participants
INTERVENTIONAL
Hefei, China
Started: Apr 1, 2025
Completed Clinical Trials
4 completed trials for Tetanus Immune Globulin (TIG) in Tetanus

The Change of the Tetanus Antibody Titer After Single Injection of Td and Simultaneous Injection of TIG With Td

NCT01338688COMPLETED
View Study
250 participants
OBSERVATIONAL
Started: Oct 1, 2008

Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus

NCT05664750COMPLETEDPHASE3
View Study
675 participants
INTERVENTIONAL
Hefei, China +27 more
Started: Dec 22, 2022

Intrathecal Tetanus Immunoglobulin to Treat Tetanus

NCT02999815COMPLETEDPHASE1, PHASE2
View Study
272 participants
INTERVENTIONAL
Ho Chi Minh City, Vietnam
Started: Feb 13, 2017

Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult Volunteers

NCT05625477COMPLETEDPHASE2
View Study
240 participants
INTERVENTIONAL
Shantou, China +3 more
Started: Apr 18, 2022